Corresponding Author: Mark Olfson, MD, MPH, Department of Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr, New York, NY 10032 (mo49@columbia.edu).
Financial Disclosures: During the past 5 years, Dr Weissman reports receipt of investigator-initiated grants from GlaxoSmithKline, Eli Lilly & Company, and the Josiah Macy Foundation. Dr Weissman reports currently receiving research funding from the National Institute of Mental Health, the National Institute on Drug Abuse, the National Association for Research on Schizophrenia and Affective Disorders, and the Sackler Foundation and receiving royalties from Oxford University Press, Perseus Press, American Psychiatric Association Press, and MultiHealth Systems. She will receive funding from the Templeton Foundation in 2010. During the past 5 years, Dr Olfson reports receipt of research support from the National Institutes of Health, the Agency for Healthcare Research and Quality, the American Foundation for Suicide Prevention, the National Association for Research on Schizophrenia and Affective Disorders, the New York State Office of Mental Health, Bristol-Myers Squibb, Eli Lilly & Company, AstraZeneca, and Ortho-McNeil Janssen Scientific Affairs. Dr Olfson reports working as a consultant for Pfizer, Janssen, Bristol-Myers Squibb, Eli Lilly & Company, and AstraZeneca and working as the scientific director of Columbia University TeenScreen.
Funding/Support: This work was supported by grant HS016097 from the Agency for Healthcare Research and Quality and grants MH036197, MH082255, MH063852, and MH071478 from the National Institute of Mental Health.
Role of the Sponsor: The sponsors had no role in the preparation, review, or approval of the manuscript.